BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12107546)

  • 1. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
    Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells.
    Adler V; Bowne W; Kamran I; Michl J; Friedman FK; Chin E; Zenilman M; Pincus MR
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):491-8. PubMed ID: 18066549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
    Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that the ras oncogene-encoded p21 protein induces oocyte maturation via activation of protein kinase C.
    Chung DL; Brandt-Rauf PW; Weinstein IB; Nishimura S; Yamaizumi Z; Murphy RB; Pincus MR
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1993-6. PubMed ID: 1542698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents.
    Amar S; Glozman A; Chung D; Adler V; Ronai Z; Friedman FK; Robinson R; Brandt-Rauf P; Yamaizumi Z; Pincus MR
    Cancer Chemother Pharmacol; 1997; 41(1):79-85. PubMed ID: 9443618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
    Luo W; Sharif TR; Houghton PJ; Sharif M
    Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic and activated wild-type ras-p21 proteins induce different isoforms of protein kinase C in mitogenic signal transduction.
    Chie L; Qu Y; Chung D; Boutjdir M; Pincus MR
    J Protein Chem; 2003 Nov; 22(7-8):625-9. PubMed ID: 14714729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of oocyte maturation by jun-N-terminal kinase (JNK) on the oncogenic ras-p21 pathway is dependent on the raf-MEK signal transduction pathway.
    Chie L; Amar S; Kung HF; Lin MC; Chen H; Chung DL; Adler V; Ronai Z; Friedman FK; Robinson RC; Kovac C; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2000; 45(6):441-9. PubMed ID: 10854130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the site of inhibition of oncogenic ras-p21-induced signal transduction by a peptide from a ras effector domain.
    Chie L; Chen JM; Friedman FK; Chung DL; Amar S; Michl J; Yamaizumi Z; Brandt-Rauf PW; Pincus MR
    J Protein Chem; 1999 Nov; 18(8):881-4. PubMed ID: 10839625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
    Okumura K; Shirasawa S; Nishioka M; Sasazuki T
    Cancer Res; 1999 May; 59(10):2445-50. PubMed ID: 10344756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of discrete apoptotic pathways by Ras.
    Chen CY; Liou J; Forman LW; Faller DV
    J Biol Chem; 1998 Jul; 273(27):16700-9. PubMed ID: 9642224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase.
    Adler V; Bowne W; Michl J; Sookraj KA; Ikram K; Pestka S; Izotova L; Zenilman M; Friedman FK; Qu Y; Pincus MR
    Ann Clin Lab Sci; 2008; 38(1):47-56. PubMed ID: 18316782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
    Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
    Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells.
    Xiao L; Lang W
    Cancer Res; 2000 Jan; 60(2):400-8. PubMed ID: 10667594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors.
    Corbley MJ; Cherington V; Traxler PM; Lydon NB; Roberts TM
    Int J Cancer; 1996 Jun; 66(6):753-9. PubMed ID: 8647645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation.
    Kovac C; Clie L; Morin J; Friedman FK; Robinson R; Chung DL; Kanovsky M; Flom J; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):9-14. PubMed ID: 11488531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione-S-Transferase as a selective inhibitor of oncogenic ras-p21-induced mitogenic signaling through blockade of activation of jun by jun-N-terminal kinase.
    Villafania A; Anwar K; Amar S; Chie L; Way D; Chung DL; Adler V; Ronai Z; Brandt-Rauf PW; Yamaizumii Z; Kung HF; Pincus MR
    Ann Clin Lab Sci; 2000 Jan; 30(1):57-64. PubMed ID: 10678584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
    Andrejauskas-Buchdunger E; Regenass U
    Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.